Targets to treatmetabolic syndrome in polycystic ovary syndrome

被引:57
作者
Mahalingaiah, Shruthi [1 ]
Diamanti-Kandarakis, Evanthia [2 ]
机构
[1] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA
[2] Univ Athens, Sch Med, Dept Diabet Endocrinol & Metab, Athens 11521, Greece
基金
美国国家卫生研究院;
关键词
group care; lifestyle modification; metabolic syndrome; polycystic ovary syndrome; CARDIOVASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE MODIFICATION; LOW-DENSITY-LIPOPROTEIN; GLYCATION END-PRODUCTS; GONADOTROPIN-RELEASING-HORMONE; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; OBESE WOMEN;
D O I
10.1517/14728222.2015.1101067
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Metabolic syndrome is comprised of a combination of the following states: increased insulin resistance, dyslipidemia, cardiovascular disease, and increased abdominal obesity. Women with polycystic ovary syndrome (PCOS) have an increased risk of developing metabolic syndrome over the course of their lives. Metabolic syndrome increases risk of major cardiovascular events, morbidity, quality of life, and overall health care costs. Though metabolic syndrome in women with PCOS is an area of great concern, there is no effective individual medical therapeutic to adequately treat this issue. Areas Covered: This article will review key aspects of metabolic syndrome in PCOS. We will discuss classic and novel therapeutics to address metabolic syndrome in women with PCOS. We will conclude with the importance of developing strategic interventions to increase the compliance to lifestyle and dietary modification, in addition to appreciation of the emerging pharmaceutical therapeutics available. Expert Opinion: Innovation in lifestyle modification, including diet, exercise, with and without dedicated stress reduction techniques is the future in treatment of metabolic syndrome in PCOS. Application of novel interventions, such as group medical care, may improve future adherence to lifestyle modification recommendations, in addition to or in combination with pharmaceutical therapeutics.
引用
收藏
页码:1561 / 1574
页数:14
相关论文
共 166 条
[51]   The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond [J].
Economou, Frangiskos ;
Xyrafis, Xenofon ;
Christakou, Charikleia ;
Diamanti-Kandarakis, Evanthia .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (09) :908-921
[52]   In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls [J].
Economou, Frangiskos ;
Xyrafis, Xenofon ;
Livadas, Sarantis ;
Androulakis, Ioannis I. ;
Argyrakopoulou, Georgia ;
Christakou, Charikleia D. ;
Kandaraki, Eleni ;
Palioura, Eleni ;
Diamanti-Kandarakis, Evanthia .
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2009, 8 (03) :199-206
[53]   Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome [J].
Ehrmann, DA ;
Barnes, RB ;
Rosenfield, RL ;
Cavaghan, MK ;
Imperial, J .
DIABETES CARE, 1999, 22 (01) :141-146
[54]  
Ehrmann DA, 2006, J CLIN ENDOCR METAB, V91, P148
[55]   Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes [J].
Erbey, JR ;
Silberman, C ;
Lydick, E .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (07) :588-590
[56]   Metabolic Heterogeneity in Polycystic Ovary Syndrome Is Determined by Obesity: Plasma Metabolomic Approach Using GC-MS [J].
Escobar-Morreale, Hector F. ;
Samino, Sara ;
Insenser, Maria ;
Vinaixa, Maria ;
Luque-Ramirez, Manuel ;
Lasuncion, Miguel A. ;
Correig, Xavier .
CLINICAL CHEMISTRY, 2012, 58 (06) :999-1009
[57]   The role of the endogenous opioid system in polycystic ovary syndrome [J].
Eyvazzadeh, Aimee D. ;
Pennington, Kathryn P. ;
Pop-Busui, Rodica ;
Sowers, MaryFran ;
Zubieta, Jon-Kar ;
Smith, Yolanda R. .
FERTILITY AND STERILITY, 2009, 92 (01) :1-12
[58]  
Farah L, 1999, J REPROD MED, V44, P870
[59]   Insulin resistance and hypersecretion in obesity [J].
Ferrannini, E ;
Natali, A ;
Bell, P ;
CavalloPerin, P ;
Lalic, N ;
Mingrone, G .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (05) :1166-1173
[60]   Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study [J].
Florakis, D. ;
Diamanti-Kandarakis, E. ;
Katsikis, I. ;
Nassis, G. P. ;
Karkanaki, A. ;
Georgopoulos, N. ;
Panidis, D. .
INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 (04) :692-699